TD Cowen upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $97, up from $90. The firm thinks the company has entered a renewed growth cycle, driven by TAVR indication expansion, reinforced Sapien durability from the seven-year PARTNER 3 results, and accelerating momentum with Evoque. TD sees a path to sustained double-digit organic growth for Edwards.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $108 from $104 at Goldman Sachs
- Becton Dickinson price target raised to $215 from $210 at Stifel
- Edwards Lifesciences price target raised to $105 from $100 at Stifel
- Edwards Lifesciences price target raised to $94 from $92 at Evercore ISI
- Edwards Lifesciences receives FDA approval for SAPIEN M3 mitral valve system